Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Summary Background The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no...
Internal Medicine | DOUBLE-BLIND | SUNITINIB | MEDICINE, GENERAL & INTERNAL | EFFICACY | CANCER | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Angiogenesis Inhibitors - adverse effects | Pyridines - therapeutic use | Imidazoles - adverse effects | Disease-Free Survival | Aged | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Carcinoma, Renal cell | Diagnosis | Research | Drug therapy | Risk factors | Complications and side effects | Axitinib | Dosage and administration | Comparative analysis | Heart attacks | Data collection | Interferon | Family medical history | Clinical medicine | Vascular endothelial growth factor | Drug dosages | Cancer
Internal Medicine | DOUBLE-BLIND | SUNITINIB | MEDICINE, GENERAL & INTERNAL | EFFICACY | CANCER | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Angiogenesis Inhibitors - adverse effects | Pyridines - therapeutic use | Imidazoles - adverse effects | Disease-Free Survival | Aged | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Carcinoma, Renal cell | Diagnosis | Research | Drug therapy | Risk factors | Complications and side effects | Axitinib | Dosage and administration | Comparative analysis | Heart attacks | Data collection | Interferon | Family medical history | Clinical medicine | Vascular endothelial growth factor | Drug dosages | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 155 - 164
Summary Background Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced...
Hematology, Oncology and Palliative Medicine | INTERLEUKIN-2 | REGRESSION | METASTATIC MELANOMA | ANTIGEN-4 BLOCKADE | THERAPY | ONCOLOGY | AUTOIMMUNITY | ANTIBODY | CTLA-4 | CONFIDENCE | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Double-Blind Method | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Melanoma - pathology | Dose-Response Relationship, Drug | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Antigens | Medical colleges | Medical research | Care and treatment | Immunotherapy | Melanoma | Monoclonal antibodies | Medicine, Experimental
Hematology, Oncology and Palliative Medicine | INTERLEUKIN-2 | REGRESSION | METASTATIC MELANOMA | ANTIGEN-4 BLOCKADE | THERAPY | ONCOLOGY | AUTOIMMUNITY | ANTIBODY | CTLA-4 | CONFIDENCE | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Double-Blind Method | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Melanoma - pathology | Dose-Response Relationship, Drug | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Antigens | Medical colleges | Medical research | Care and treatment | Immunotherapy | Melanoma | Monoclonal antibodies | Medicine, Experimental
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 552 - 562
Summary Background In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell...
Hematology, Oncology and Palliative Medicine | PROGNOSTIC-FACTORS | EFFICACY | EVEROLIMUS | BIOMARKER | ONCOLOGY | PROGRESSION-FREE SURVIVAL | Niacinamide - analogs & derivatives | Multivariate Analysis | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Carcinoma, Renal Cell - enzymology | Female | Surveys and Questionnaires | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Imidazoles - adverse effects | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Intention to Treat Analysis | Quality of Life | Kidney Neoplasms - pathology | Aged | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Clinical trials | Care and treatment | Carcinoma, Renal cell | Analysis | Patient outcomes
Hematology, Oncology and Palliative Medicine | PROGNOSTIC-FACTORS | EFFICACY | EVEROLIMUS | BIOMARKER | ONCOLOGY | PROGRESSION-FREE SURVIVAL | Niacinamide - analogs & derivatives | Multivariate Analysis | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Carcinoma, Renal Cell - enzymology | Female | Surveys and Questionnaires | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Imidazoles - adverse effects | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Intention to Treat Analysis | Quality of Life | Kidney Neoplasms - pathology | Aged | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Clinical trials | Care and treatment | Carcinoma, Renal cell | Analysis | Patient outcomes
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 7, pp. 673 - 680
Summary Background Combining targeted treatments for renal cell carcinoma has been suggested as a possible method to improve treatment efficacy. We aimed to...
Hematology, Oncology and Palliative Medicine | TARGETED THERAPY | EVEROLIMUS | ONCOLOGY | CLINICAL-TRIALS | DOUBLE-BLIND | AGENTS | ANTITUMOR-ACTIVITY | COMBINATION | FAILURE | III TRIAL | KIDNEY CANCER | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Humans | Middle Aged | Interferon-alpha - therapeutic use | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Antibodies, Monoclonal, Humanized | Disease-Free Survival | Aged, 80 and over | Adult | Female | Indoles - therapeutic use | Aged | Carcinoma, Renal Cell - drug therapy | Neoplasm Staging | Pyrroles - therapeutic use | Care and treatment | Carbamates | Product development | Interferon | Metastasis | Carcinoma, Renal cell | Biological response modifiers | Vascular endothelial growth factor | Index Medicus
Hematology, Oncology and Palliative Medicine | TARGETED THERAPY | EVEROLIMUS | ONCOLOGY | CLINICAL-TRIALS | DOUBLE-BLIND | AGENTS | ANTITUMOR-ACTIVITY | COMBINATION | FAILURE | III TRIAL | KIDNEY CANCER | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Humans | Middle Aged | Interferon-alpha - therapeutic use | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Antibodies, Monoclonal, Humanized | Disease-Free Survival | Aged, 80 and over | Adult | Female | Indoles - therapeutic use | Aged | Carcinoma, Renal Cell - drug therapy | Neoplasm Staging | Pyrroles - therapeutic use | Care and treatment | Carbamates | Product development | Interferon | Metastasis | Carcinoma, Renal cell | Biological response modifiers | Vascular endothelial growth factor | Index Medicus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its...
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 2, pp. 115 - 124
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. Renal-cell carcinoma of the...
PHASE-III TRIAL | SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | FUNCTIONAL ASSESSMENT | DOSE RECOMBINANT INTERLEUKIN-2 | VALIDATION | TYROSINE KINASE INHIBITOR | RANDOMIZED-TRIAL | SU11248 | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Risk Factors | Interferon-alpha - therapeutic use | Kaplan-Meier Estimate | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Quality of Life | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Interferon alpha | Clinical trials | Interferon | Cytokines | Vascular endothelial growth factor | Skin cancer
PHASE-III TRIAL | SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | FUNCTIONAL ASSESSMENT | DOSE RECOMBINANT INTERLEUKIN-2 | VALIDATION | TYROSINE KINASE INHIBITOR | RANDOMIZED-TRIAL | SU11248 | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Risk Factors | Interferon-alpha - therapeutic use | Kaplan-Meier Estimate | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Quality of Life | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Interferon alpha | Clinical trials | Interferon | Cytokines | Vascular endothelial growth factor | Skin cancer
Journal Article